ZA200205162B - Linezolid-crystal Form II. - Google Patents
Linezolid-crystal Form II. Download PDFInfo
- Publication number
- ZA200205162B ZA200205162B ZA200205162A ZA200205162A ZA200205162B ZA 200205162 B ZA200205162 B ZA 200205162B ZA 200205162 A ZA200205162 A ZA 200205162A ZA 200205162 A ZA200205162 A ZA 200205162A ZA 200205162 B ZA200205162 B ZA 200205162B
- Authority
- ZA
- South Africa
- Prior art keywords
- process according
- solvent
- phenyl
- fluoro
- morpholinyl
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims description 22
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims description 41
- 229960003907 linezolid Drugs 0.000 claims description 40
- 239000002904 solvent Substances 0.000 claims description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 25
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 238000001228 spectrum Methods 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 239000008096 xylene Substances 0.000 claims description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- -1 methyl ethyl Chemical group 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17983700P | 2000-02-02 | 2000-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200205162B true ZA200205162B (en) | 2003-09-29 |
Family
ID=22658183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200205162A ZA200205162B (en) | 2000-02-02 | 2002-06-27 | Linezolid-crystal Form II. |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP1255754B1 (xx) |
| JP (1) | JP5235256B2 (xx) |
| KR (3) | KR100781815B1 (xx) |
| CN (1) | CN1221547C (xx) |
| AR (1) | AR027261A1 (xx) |
| AT (1) | ATE297920T1 (xx) |
| AU (1) | AU782138B2 (xx) |
| BR (1) | BR0107667A (xx) |
| CA (1) | CA2395603C (xx) |
| CO (1) | CO5261555A1 (xx) |
| CZ (1) | CZ302292B6 (xx) |
| DE (1) | DE60111497T2 (xx) |
| DK (1) | DK1255754T3 (xx) |
| EA (1) | EA004434B1 (xx) |
| EE (1) | EE05197B1 (xx) |
| ES (1) | ES2242728T3 (xx) |
| HK (1) | HK1051196A1 (xx) |
| HU (1) | HUP0301076A3 (xx) |
| IL (1) | IL151010A0 (xx) |
| MX (1) | MXPA02007471A (xx) |
| MY (1) | MY122829A (xx) |
| NO (2) | NO323459B1 (xx) |
| NZ (1) | NZ520541A (xx) |
| PE (1) | PE20011086A1 (xx) |
| PL (1) | PL356433A1 (xx) |
| PT (1) | PT1255754E (xx) |
| SI (1) | SI1255754T1 (xx) |
| SK (1) | SK287025B6 (xx) |
| TW (1) | TWI297687B (xx) |
| WO (1) | WO2001057035A1 (xx) |
| ZA (1) | ZA200205162B (xx) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100490643B1 (ko) * | 2002-10-29 | 2005-05-19 | 한국과학기술연구원 | 새로운 메틸리덴 피페리딘일 옥사졸리딘온 유도체 및이들의 제조방법 |
| HUE051230T2 (hu) | 2003-10-16 | 2021-03-01 | Symed Labs Ltd | Linezolid kristályos formája |
| DE602004009344T2 (de) | 2004-04-19 | 2008-07-10 | Symed Labs Ltd., Hyderabad | Neues verfahren zur herstellung von linezolid und verwandten verbindungen |
| EP1745028A2 (en) * | 2004-06-29 | 2007-01-24 | Teva Pharmaceutical Industries Ltd | Solid forms of linezolid and processes for preparation thereof |
| CA2572054A1 (en) * | 2004-06-29 | 2006-01-12 | Teva Pharmaceutical Industries Ltd. | Crystalline form iv of linezolid |
| EP1866295A2 (en) | 2005-02-24 | 2007-12-19 | Teva Pharmaceutical Industries Ltd | Processes for the preparation of linezolid intermediate |
| JP2008514734A (ja) * | 2005-06-22 | 2008-05-08 | テバ ファーマシューティカル インダストリーズ リミティド | マレイン酸テガセロドの多型体 |
| ATE400257T1 (de) * | 2005-07-20 | 2008-07-15 | Teva Pharma | Stabile pharmazeutische zusammensetzung mit linezolid form iv |
| WO2007102082A1 (en) * | 2006-03-09 | 2007-09-13 | Glenmark Pharmaceuticals Limited | High oxazolidinone content solid dosage forms |
| WO2008127300A2 (en) * | 2006-10-23 | 2008-10-23 | Concert Pharmaceuticals Inc. | Oxazolidinone derivatives and methods of use |
| WO2011050826A1 (en) | 2009-10-28 | 2011-05-05 | Synthon B.V. | Process for making crystalline form a of linezolid |
| RU2012151303A (ru) | 2010-04-30 | 2014-06-10 | Индиана Юниверсити Рисерч Эдн Текнолоджи Корпорейшн | Способы получения линезолида |
| WO2012019632A1 (en) | 2010-08-11 | 2012-02-16 | Synthon B.V. | Process for making linezolid |
| EP2603506A1 (en) | 2010-08-11 | 2013-06-19 | Synthon BV | Process for making linezolid |
| EP2593440A1 (en) * | 2011-02-24 | 2013-05-22 | Lee Pharma Limited | Anhydrous linezolid crystalline form-ii |
| WO2012119653A1 (en) | 2011-03-09 | 2012-09-13 | Synthon Bv | Process for making crystalline form a of linezolid |
| CN102731341A (zh) * | 2011-04-13 | 2012-10-17 | 上海医药工业研究院 | 用于制备利奈唑胺的中间体及其制备方法 |
| CN105461648B (zh) * | 2011-05-03 | 2018-01-12 | 江苏豪森药业集团有限公司 | 利奈唑胺的晶型及其制备方法 |
| CN102399200B (zh) * | 2011-12-14 | 2013-12-04 | 浙江新东港药业股份有限公司 | 一种利用悬浮结晶法制备利奈唑胺晶型ⅰ的方法 |
| WO2013111048A1 (en) | 2012-01-24 | 2013-08-01 | Jubilant Life Sciences Limited | Improved process for the preparation of stable crystalline form-i of linezolid, substantially free of residual solvent |
| WO2013120496A1 (en) | 2012-02-14 | 2013-08-22 | Pharmathen S.A. | Process for the preparation of linezolid in crystalline form and salts thereof |
| CN102643245A (zh) * | 2012-04-10 | 2012-08-22 | 杭州华东医药集团生物工程研究所有限公司 | 一种利奈唑胺晶型及其制备方法 |
| ES2603252T3 (es) | 2012-11-09 | 2017-02-24 | Synthon Bv | Proceso para preparar linezolid |
| CN111432800B (zh) | 2017-11-16 | 2023-12-15 | 佩尔西卡制药有限公司 | 利奈唑胺制剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK283420B6 (sk) * | 1992-05-08 | 2003-07-01 | Pharmacia & Upjohn Company | Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny |
| MY115155A (en) * | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| US5688792A (en) * | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
| CZ298060B6 (cs) * | 1996-04-11 | 2007-06-06 | Pharmacia & Upjohn Company | Zpusob prípravy oxazolidinonu |
| KR100619639B1 (ko) * | 1997-11-07 | 2006-09-06 | 파마시아 앤드 업존 캄파니 엘엘씨 | 옥사졸리디논의 제조 방법 |
-
2001
- 2001-01-22 AR ARP010100269A patent/AR027261A1/es not_active Application Discontinuation
- 2001-01-25 PE PE2001000080A patent/PE20011086A1/es not_active Application Discontinuation
- 2001-01-26 CO CO01005901A patent/CO5261555A1/es not_active Application Discontinuation
- 2001-01-29 EA EA200200819A patent/EA004434B1/ru not_active IP Right Cessation
- 2001-01-29 EP EP01904805A patent/EP1255754B1/en not_active Expired - Lifetime
- 2001-01-29 DE DE60111497T patent/DE60111497T2/de not_active Expired - Lifetime
- 2001-01-29 PL PL01356433A patent/PL356433A1/xx unknown
- 2001-01-29 SK SK994-2002A patent/SK287025B6/sk not_active IP Right Cessation
- 2001-01-29 BR BR0107667-1A patent/BR0107667A/pt not_active Application Discontinuation
- 2001-01-29 NZ NZ520541A patent/NZ520541A/en not_active IP Right Cessation
- 2001-01-29 JP JP2001557867A patent/JP5235256B2/ja not_active Expired - Lifetime
- 2001-01-29 KR KR1020027009923A patent/KR100781815B1/ko not_active IP Right Cessation
- 2001-01-29 HU HU0301076A patent/HUP0301076A3/hu unknown
- 2001-01-29 MX MXPA02007471A patent/MXPA02007471A/es active IP Right Grant
- 2001-01-29 MY MYPI20010371A patent/MY122829A/en unknown
- 2001-01-29 ES ES01904805T patent/ES2242728T3/es not_active Expired - Lifetime
- 2001-01-29 AT AT01904805T patent/ATE297920T1/de active
- 2001-01-29 CN CNB018034489A patent/CN1221547C/zh not_active Expired - Fee Related
- 2001-01-29 PT PT01904805T patent/PT1255754E/pt unknown
- 2001-01-29 CA CA2395603A patent/CA2395603C/en not_active Expired - Lifetime
- 2001-01-29 EE EEP200200420A patent/EE05197B1/xx not_active IP Right Cessation
- 2001-01-29 AU AU32755/01A patent/AU782138B2/en not_active Ceased
- 2001-01-29 DK DK01904805T patent/DK1255754T3/da active
- 2001-01-29 WO PCT/US2001/000657 patent/WO2001057035A1/en active IP Right Grant
- 2001-01-29 IL IL15101001A patent/IL151010A0/xx active IP Right Grant
- 2001-01-29 SI SI200130405T patent/SI1255754T1/sl unknown
- 2001-01-29 KR KR1020077016678A patent/KR100864745B1/ko not_active IP Right Cessation
- 2001-01-29 KR KR1020087010742A patent/KR20080044358A/ko not_active Application Discontinuation
- 2001-01-29 CZ CZ20022635A patent/CZ302292B6/cs not_active IP Right Cessation
- 2001-02-02 TW TW090102231A patent/TWI297687B/zh not_active IP Right Cessation
-
2002
- 2002-06-27 ZA ZA200205162A patent/ZA200205162B/en unknown
- 2002-08-01 NO NO20023654A patent/NO323459B1/no not_active IP Right Cessation
-
2003
- 2003-05-16 HK HK03103460A patent/HK1051196A1/xx not_active IP Right Cessation
-
2006
- 2006-12-15 NO NO20065836A patent/NO20065836L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6444813B2 (en) | Linezolid-crystal form II | |
| CA2395603C (en) | Linezolid-crystal form ii | |
| EP1673370B1 (en) | Crystalline form of linezolid | |
| EP1699773A2 (en) | Processes for preparation of crystalline mycophenolate sodium | |
| WO2011051384A1 (en) | Process for making crystalline form a of linezolid | |
| JP2007524569A (ja) | ナテグリニドの結晶形 | |
| EP2825525A1 (en) | New polymorphic form of a long-acting beta-2 adrenoceptor agonist | |
| EP4188905A1 (en) | Method for the purification of vilanterol trifenatate | |
| EP2493867A1 (en) | Process for making crystalline form a of linezolid |